K1-70 - A Study in Subjects With Graves' Disease

Status Completed

Clinical Trial Summary

This study is the first time that K1-70 will be administered to humans. The principal aim of this study is to obtain safety and tolerability data when K1-70 is administered as an IM injection or as an IV infusion to subjects with Graves' disease. Current therapy for Graves' disease includes treatment with anti-thyroid drugs, destruction of the thyroid using radioiodine, or total surgical thyroidectomy. Beta-blockers and calcium antagonists may be used to control some of the symptoms of hyperthyroidism. K1-70 is a thyroid stimulating hormone receptor antagonist that may provide new in vivo diagnostic and therapeutic tools for the management of patients with Graves' disease, patients with thyroid cancer and patients who would benefit from controlling receptor activity.

Clinical Trial Description

Graves' disease is one of the most common overt autoimmune disorders. Patients with Graves' disease have thyroid over activity and hyperthyroidism. Symptoms of hyperthyroidism include goitre, fatigue, heat intolerance, sweating, weight loss despite good appetite, shakiness, inappropriate anxiety, palpitations of the heart, shortness of breath, tetchiness and agitation, poor sleep, thirst, nausea and increased frequency of defaecation. The rationale of this study is to obtain safety and tolerability data when K1-70 is administered as an intramuscular injection or as an IV infusion to subjects with Graves' disease. This information, together with the pharmacokinetic data, will help establish the doses and dosage regimen suitable for repeat administration to patients. This is an open-label study. The expected duration of each subject's participation in the study is approximately 18 weeks (including a screening period of up to 4 weeks). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02904330
Study type	Interventional
Source	AV7 Limited
Contact
Status	Completed
Phase	Phase 1
Start date	August 2016
Completion date	April 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01950260` - Early Levothyroxine Post Radioactive Iodine	Phase 2/Phase 3
Completed	`NCT01269749` - Radioactive Iodide Therapy for Pediatric Graves' Disease	Phase 2
Recruiting	`NCT06068179` - Graves' Disease Remission Study: MycoMeth Combo	Phase 2/Phase 3
Recruiting	`NCT02114619` - Comparative Study of Different I-131 Doses in Graves' Disease	N/A
Completed	`NCT04383795` - Change of Gut Microbiome in the Treatment of Graves' Disease
Completed	`NCT02384668` - D-vitamin And Graves' Disease; Morbidity And Relapse Reduction	N/A
Completed	`NCT01885533` - Post-Radioiodine Graves' Management: The PRAGMA-Study	N/A
Completed	`NCT01534169` - Function of Regulatory T Cells Improved by Dexamethasone in Graves' Patients	Phase 1
Completed	`NCT00917241` - Prevention Relapse of Graves' Disease by Intrathyroid Injection of Dexamethasone	Phase 4
Completed	`NCT00004660` - Randomized Study of Sequential Orbital Radiotherapy for Graves' Ophthalmopathy	N/A
Completed	`NCT02205801` - Study of the Efficacy of Local Analgesia as an Adjunct to General Anesthesia in Thyroidectomy and Parathyroidectomy	N/A
Recruiting	`NCT02620085` - Thyroid Disease and Personality Study	N/A
Completed	`NCT00958113` - Autoimmune Thyroid Disease Genetic Study	N/A
Completed	`NCT02727738` - Treatment of Graves' Hyperthyroidism With Selenium Plus Methimazole	N/A
Completed	`NCT00697528` - Color Doppler Imaging of Orbital Venous Flow in Grave's Orbitopathy	N/A
Completed	`NCT00150124` - Block-replacement Therapy During Radioiodine Therapy	Phase 4
Completed	`NCT03535090` - Coagulation After Intravenous Methylprednisolone Administration
Not yet recruiting	`NCT02373995` - Role of the Microbiome in Graves' Orbitopathy	Phase 1/Phase 2
Completed	`NCT00505011` - Genetic Polymorphisms Associated With Cigarette Smoking and Risk of Graves’ Disease	N/A
Completed	`NCT02107794` - Shared Decision Making in Graves Disease - Graves Disease (GD) Choice	N/A